Patient Engagement: Early Cancer Detection Blood Draw

Elligo Health Research® was tasked by a pharmaceutical company to recruit subjects for a Phase III study called DETECT-ASCEND 2, focusing on Plasma-Based CancerSEEK Testing. CancerSEEK is a liquid biopsy designed to detect various cancers in their early stages. Despite facing processing constraints with the central laboratory, which could only handle 55 samples daily, Elligo adopted a targeted decentralized approach.

They successfully enrolled 6,400 participants across 19 sites within 4.5 months. To manage limitations and ensure inclusivity, Elligo adjusted its enrollment targets to 5,391 subjects and extended enrollment by a month. Additionally, to meet sponsor requirements, they prioritized enrolling males aged 60 and above for the final two months.

Discover the other ways Elligo was able to assist the pharmaceutical company by downloading the case study below.